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Letter to the Editor. 
Carlos Corredor. 
 
A problematic enzyme 
 
Dr Fell's comments on our Open Question in the September 1984 
issue of TIBS 'Is phosphofructokinase the rate limiting step of 
glycolysis?' were grate fully received. They are however, directed 
toward minor points related to the formal, theoretical treatment and 
they miss the main point we tried to raise, namely, that the sensitivity 
coefficient (control strength) for phosphofructokinase depends not only 
on the set of experimental conditions chosen (effectors, pH, state of 
aggregation of the enzyme) but also on the type of cell and on the type 
of organism in question. 
 
We would like to point out that different terms have been used by 
different authors when describing similar concepts pertaining to control 
analysis, Only recently has a standard terminology been submitted for 
study to the IUB committee on Nomenclature. 
 
Three further comments: 
 
If one ignores the value of Z for an enzyme in different types of cells, a 
good approach to approximate its participation in the control of 
metabolic flux is to calculate the mass action ratio and constant 
independently of the cell type, the fructose 1,6-bisphosphate/fructose 
6-phosphate ([F1,6P2]/[F6P]) ratio gives a good approximation to 
changes in the ratio for phosphofructokinase (PFK). 
 
We gave the Km value for F1,6P 2 for mammalian aldolase that is 
lower than the one for yeast aldolase. At any rate, the fact that the F1, 
6P 2 concentration in glucose-consuming yeast is ~ 4 mM gives a 
[substrate]/Km ratio higher than 10 and thus aldolase should be 
saturated by its substrate. 
 
Calculations that leave glyceraldehyde-3-phosphate dehydrogenase 
(and perhaps other enzymes down the pathway) out of the glycolytic 
flux control do not explain the accumulation of F1,6P 2 observed in 
some cell types. 
We acknowledge that classification of PFK types according to 
[F6P]/[F1,6P2] ratios is an oversimplification and that the solution to 
the problem could be to calculate Z values for PFK from different 
sources under standardized conditions. This cannot be done with the 
data found in the literature but would be a very interesting project for 
future experimental work. 
 
As far as Dr Porteous' letter is concerned, we must emphasize that we 
did not purport to use the concepts of Kacser and Burns except as an 
introduction to call attention to our main point. 
It would be improper here to attempt a criticism of that theory, but it is 
important to point out that if one uses it without due attention to the 
physiological context in which enzymes work, one must overlook the 
facts that: metabolic pathways are seldom linear; there are enzymes 
that do not exhibit Michaelis kinetics (some of which are precisely 
those claimed to control a pathway, e.g. PFK and pyruvate kinase); the 
precise available concentrations of free substrates in a cell are not 
always known and in fact, for some, it is only a fraction of the total 
concentration, e.g. F1,6P2; in a cell, both substrates and products are 
continuously available to the enzyme; effectors change the 
conformation and thus the activity of certain enzymes; and there are 
protein-protein interactions at physiological enzyme concentrations that 
considerably modify the in vitro kinetics. As expected, all this is well 
understood by Dr Racker. 
 
 
 
 
  
  
